Fibrodysplasia ossificans progressiva (FOP), also known as myositis ossificans progressive, is a rare inherited connective tissue disorder characterized by abnormal bone development in ligaments, tendons, and skeletal muscles. Precisely, FOP causes the body's skeletal muscles and soft connective tissues to undergo a metamorphosis, transforming into bone, gradually locking joints and making movement difficult. FOP is inherited as an autosomal dominant trait with complete penetrance. Standard therapies available for FOP are; corticosteroids and non-steroidal anti-inflammatory medication for pain and swelling associated with FOP; occupational therapy; and genetic counselling. Regeneron Pharmaceuticals Inc. is in the process of developing REGN2477 as an activin A antibody which act as an activin modulator for the treatment of FOP. Some of the companies in FOP pipeline are Clementia Pharmaceuticals Inc. and Regeneron Pharmaceuticals Inc. among others.
-
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
-
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
